AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Forest Laboratories Inc and Gedeon Richter Plc unveil positive Phase III results of antipsychotic agent cariprazine.
(From Pharma)
M2PHARMA-February 8, 2012-Forest Laboratories Inc and Gedeon Richter Plc unveil positive Phase III results of antipsychotic agent cariprazine (C)2012 M2 COMMUNICATIONS http://www.m2.com
Forest Laboratories Inc (NYSE: FRX) and Gedeon Richter Plc on Wednesday announced preliminary top-line results from a Phase III clinical trial of cariprazine (RGH-188), an investigational antipsychotic agent, in patients with acute mania associated with bipolar I disorder.
For the primary endpoint, the Young Mania Rating Scale (YMRS), the data showed that cariprazine treated patients with acute manic episodes experienced improvements in symptoms compared to …
-
- Forest Laboratories Inc and Cypress Bioscience Inc announce results of Phase...
-
News wire article from: Asia Africa Intelligence Wire
September 28, 2005
700+ words
-
- Forest Laboratories Inc announces positive Phase III results for...
-
News wire article from: Europe Intelligence Wire
March 13, 2012
700+ words
-
- Cypress Bioscience Inc and Forest Laboratories Inc to commence the second...
-
News wire article from: Asia Africa Intelligence Wire
September 9, 2004
700+ words
-
- Almirall announces receipt of $15 M (EUR 10.5 M) from Forest Laboratories in...
-
News wire article from: Chemical Business Newsbase
September 23, 2008
700+ words
-
- Press Release: Forest Laboratories reports positive results of a Phase III...
-
News wire article from: Asia Africa Intelligence Wire
September 10, 2002
700+ words
